论文部分内容阅读
[目的]探讨同步放化疗联合厄罗替尼治疗食管癌的可行性和疗效。[方法]24例初治食管癌患者,采用根治性同步放化疗,放疗剂量60Gy(分两阶段进行),放疗的第一周和第四周给予紫杉醇和顺铂化疗。放疗第1d起口服厄罗替尼片150mg/d直至放疗结束。[结果]83.3%的患者完成了足量的治疗,治疗有效率达95%。总的2年生存率为68.31%,2年局控率为87.50%,2年无复发生存率为54.57%。Ⅲ级以上白细胞下降和血小板减少发生率分别为16.68%(4/24)和8.33%(2/24)。Ⅰ～Ⅱ期患者2年生存率及无复发生存率优于Ⅲ～Ⅳ期患者,但无显著性差异。[结论]同步放化疗联合厄罗替尼治疗食管癌生存率和局控率较好,毒副反应可耐受。
[Objective] To investigate the feasibility and efficacy of concurrent chemoradiation combined with erlotinib in the treatment of esophageal cancer. [Method] Twenty-four patients with newly diagnosed esophageal cancer underwent concurrent chemoradiotherapy with 60 Gy of radiotherapy (in two stages). Paclitaxel and cisplatin were given in the first and fourth week of radiotherapy. From the first day of radiotherapy, oral administration of erlotinib 150mg / d until the end of radiotherapy. [Results] 83.3% of patients completed adequate treatment, the effective rate was 95%. The overall 2-year survival rate was 68.31%, the 2-year local control rate was 87.50%, and the 2-year recurrence-free survival rate was 54.57%. Grade Ⅲ leukopenia and thrombocytopenia were 16.68% (4/24) and 8.33% (2/24) respectively. The 2-year survival and recurrence-free survival of stage Ⅰ ~ Ⅱ patients were better than those of stage Ⅲ ~ Ⅳ patients, but there was no significant difference. [Conclusions] The concurrent chemoradiotherapy combined with erlotinib treatment of esophageal cancer survival rate and local control rate is good, toxic side effects can be tolerated.